Cargando…

Assessment of cells in the ascitic fluid of women with ovarian hyperstimulation syndrome: the clinical implications for subsequent ovarian malignancy

BACKGROUND: Although some studies have reported a potential connection between ovulation induction therapy (OIT) and malignant ovarian diseases, the results have been inconclusive. In the present study, we sought to determine whether women undergoing OIT at our in vitro fertilization (IVF) clinic, e...

Descripción completa

Detalles Bibliográficos
Autores principales: Hatzipetros, Ioannis, Gocze, Peter M, Cziraky, Katalin, Kovacs, Kalman, Kalman, Endre, Farkas, Balint
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3847118/
https://www.ncbi.nlm.nih.gov/pubmed/24028152
http://dx.doi.org/10.1186/1477-7827-11-91
_version_ 1782293543511916544
author Hatzipetros, Ioannis
Gocze, Peter M
Cziraky, Katalin
Kovacs, Kalman
Kalman, Endre
Farkas, Balint
author_facet Hatzipetros, Ioannis
Gocze, Peter M
Cziraky, Katalin
Kovacs, Kalman
Kalman, Endre
Farkas, Balint
author_sort Hatzipetros, Ioannis
collection PubMed
description BACKGROUND: Although some studies have reported a potential connection between ovulation induction therapy (OIT) and malignant ovarian diseases, the results have been inconclusive. In the present study, we sought to determine whether women undergoing OIT at our in vitro fertilization (IVF) clinic, especially those with severe ovarian hyperstimulation syndrome (OHSS) and suspicious cytologic findings, were at risk for developing malignant ovarian tumours after treatment. METHODS: Patients who underwent OIT at our IVF clinic were enrolled in this study and assessed for any evidence of malignant ovarian tumours. Patients who developed severe OHSS as a result of OIT were treated with a culdocentesis. Cells from the ascitic fluid were cytologically scored for abnormality and malignancy. Peripheral blood samples were obtained from patients with severe OHSS to determine serum levels of the tumour markers (CA-125 and HE4) that were used to calculate the Risk for Ovarian Malignancy Algorithm (ROMA) index. RESULTS: Follow-up data were available for 1,353 of the 1,587 patients (85%) who underwent OIT at our IVF clinic between January 2006 and December 2012. Twenty-three patients (1.4%) were hospitalized with OHSS. Culdocentesis was performed 16 times in nine patients with severe OHSS (age range, 23–34 years; mean, 27.1 years). Although cytological examination of the ascitic cells of these patients suggested malignant ovarian neoplasia, over the course of the observation period, the ovarian volume gradually decreased and became normal. Subsequent cytological and histological examinations failed to find evidence of any malignant tumours in these nine patients. None of the 1,353 participants who underwent OIT developed any malignant ovarian tumours during the study period. Moreover, none of the 462 patients who were in our ovarian tumour registry were also participants in the IVF program. CONCLUSIONS: The presence of atypical cells in the ascitic fluid of women with severe OHSS does not likely indicate malignancy; therefore, radical surgical intervention is not justified. The risk of malignancy is minimal shortly after OIT. At our centre, OIT has not been associated with any cases of ovarian tumour.
format Online
Article
Text
id pubmed-3847118
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-38471182013-12-04 Assessment of cells in the ascitic fluid of women with ovarian hyperstimulation syndrome: the clinical implications for subsequent ovarian malignancy Hatzipetros, Ioannis Gocze, Peter M Cziraky, Katalin Kovacs, Kalman Kalman, Endre Farkas, Balint Reprod Biol Endocrinol Research BACKGROUND: Although some studies have reported a potential connection between ovulation induction therapy (OIT) and malignant ovarian diseases, the results have been inconclusive. In the present study, we sought to determine whether women undergoing OIT at our in vitro fertilization (IVF) clinic, especially those with severe ovarian hyperstimulation syndrome (OHSS) and suspicious cytologic findings, were at risk for developing malignant ovarian tumours after treatment. METHODS: Patients who underwent OIT at our IVF clinic were enrolled in this study and assessed for any evidence of malignant ovarian tumours. Patients who developed severe OHSS as a result of OIT were treated with a culdocentesis. Cells from the ascitic fluid were cytologically scored for abnormality and malignancy. Peripheral blood samples were obtained from patients with severe OHSS to determine serum levels of the tumour markers (CA-125 and HE4) that were used to calculate the Risk for Ovarian Malignancy Algorithm (ROMA) index. RESULTS: Follow-up data were available for 1,353 of the 1,587 patients (85%) who underwent OIT at our IVF clinic between January 2006 and December 2012. Twenty-three patients (1.4%) were hospitalized with OHSS. Culdocentesis was performed 16 times in nine patients with severe OHSS (age range, 23–34 years; mean, 27.1 years). Although cytological examination of the ascitic cells of these patients suggested malignant ovarian neoplasia, over the course of the observation period, the ovarian volume gradually decreased and became normal. Subsequent cytological and histological examinations failed to find evidence of any malignant tumours in these nine patients. None of the 1,353 participants who underwent OIT developed any malignant ovarian tumours during the study period. Moreover, none of the 462 patients who were in our ovarian tumour registry were also participants in the IVF program. CONCLUSIONS: The presence of atypical cells in the ascitic fluid of women with severe OHSS does not likely indicate malignancy; therefore, radical surgical intervention is not justified. The risk of malignancy is minimal shortly after OIT. At our centre, OIT has not been associated with any cases of ovarian tumour. BioMed Central 2013-09-12 /pmc/articles/PMC3847118/ /pubmed/24028152 http://dx.doi.org/10.1186/1477-7827-11-91 Text en Copyright © 2013 Hatzipetros et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Hatzipetros, Ioannis
Gocze, Peter M
Cziraky, Katalin
Kovacs, Kalman
Kalman, Endre
Farkas, Balint
Assessment of cells in the ascitic fluid of women with ovarian hyperstimulation syndrome: the clinical implications for subsequent ovarian malignancy
title Assessment of cells in the ascitic fluid of women with ovarian hyperstimulation syndrome: the clinical implications for subsequent ovarian malignancy
title_full Assessment of cells in the ascitic fluid of women with ovarian hyperstimulation syndrome: the clinical implications for subsequent ovarian malignancy
title_fullStr Assessment of cells in the ascitic fluid of women with ovarian hyperstimulation syndrome: the clinical implications for subsequent ovarian malignancy
title_full_unstemmed Assessment of cells in the ascitic fluid of women with ovarian hyperstimulation syndrome: the clinical implications for subsequent ovarian malignancy
title_short Assessment of cells in the ascitic fluid of women with ovarian hyperstimulation syndrome: the clinical implications for subsequent ovarian malignancy
title_sort assessment of cells in the ascitic fluid of women with ovarian hyperstimulation syndrome: the clinical implications for subsequent ovarian malignancy
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3847118/
https://www.ncbi.nlm.nih.gov/pubmed/24028152
http://dx.doi.org/10.1186/1477-7827-11-91
work_keys_str_mv AT hatzipetrosioannis assessmentofcellsintheasciticfluidofwomenwithovarianhyperstimulationsyndrometheclinicalimplicationsforsubsequentovarianmalignancy
AT goczepeterm assessmentofcellsintheasciticfluidofwomenwithovarianhyperstimulationsyndrometheclinicalimplicationsforsubsequentovarianmalignancy
AT czirakykatalin assessmentofcellsintheasciticfluidofwomenwithovarianhyperstimulationsyndrometheclinicalimplicationsforsubsequentovarianmalignancy
AT kovacskalman assessmentofcellsintheasciticfluidofwomenwithovarianhyperstimulationsyndrometheclinicalimplicationsforsubsequentovarianmalignancy
AT kalmanendre assessmentofcellsintheasciticfluidofwomenwithovarianhyperstimulationsyndrometheclinicalimplicationsforsubsequentovarianmalignancy
AT farkasbalint assessmentofcellsintheasciticfluidofwomenwithovarianhyperstimulationsyndrometheclinicalimplicationsforsubsequentovarianmalignancy